Barge RM - Search Results

1

Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience.

Barge RM, Starrenburg CW, Falkenburg JH, Fibbe WE, Marijt EW, Willemze R. Barge RM, et al. Bone Marrow Transplant. 2006 Jun;37(12):1129-34. doi: 10.1038/sj.bmt.1705385. Bone Marrow Transplant. 2006. PMID: 16757974

2

Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors.

Barge RM, Osanto S, Marijt WA, Starrenburg CW, Fibbe WE, Nortier JW, Falkenburg JH, Willemze R. Barge RM, et al. Exp Hematol. 2003 Oct;31(10):865-72. doi: 10.1016/s0301-472x(03)00200-5. Exp Hematol. 2003. PMID: 14550801 Free article.

3

Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.

Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH. Posthuma EF, et al. Among authors: barge rm. Biol Blood Marrow Transplant. 2004 Mar;10(3):204-12. doi: 10.1016/j.bbmt.2003.11.003. Biol Blood Marrow Transplant. 2004. PMID: 14993886 Free article.

4

Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab.

von dem Borne PA, Beaumont F, Starrenburg CW, Oudshoorn M, Hale G, Falkenburg JH, Fibbe WE, Willemze R, Barge RM. von dem Borne PA, et al. Among authors: barge rm. Haematologica. 2006 Nov;91(11):1559-62. Haematologica. 2006. PMID: 17082014

5

Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome.

Barge RM, Brouwer RE, Beersma MF, Starrenburg CW, Zwinderman AH, Hale G, Waldmann H, den Ottolander GJ, Falkenburg JH, Willemze R, Fibbe WE. Barge RM, et al. Bone Marrow Transplant. 2001 May;27(10):1053-8. doi: 10.1038/sj.bmt.1703024. Bone Marrow Transplant. 2001. PMID: 11438820

6

Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.

van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF. van der Heiden PL, et al. Among authors: barge rm. Bone Marrow Transplant. 2006 Apr;37(7):693-8. doi: 10.1038/sj.bmt.1705311. Bone Marrow Transplant. 2006. PMID: 16501590

7

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.

Jedema I, Barge RM, van der Velden VH, Nijmeijer BA, van Dongen JJ, Willemze R, Falkenburg JH. Jedema I, et al. Among authors: barge rm. Leukemia. 2004 Feb;18(2):316-25. doi: 10.1038/sj.leu.2403205. Leukemia. 2004. PMID: 14614514

8

Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy.

Hoogendoorn M, Wolbers JO, Smit WM, Schaafsma MR, Barge RM, Willemze R, Falkenburg JH. Hoogendoorn M, et al. Among authors: barge rm. Leukemia. 2004 Jul;18(7):1278-87. doi: 10.1038/sj.leu.2403358. Leukemia. 2004. PMID: 15116118

9

Primary allogeneic T-cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation.

Hoogendoorn M, Olde Wolbers J, Smit WM, Schaafsma MR, Jedema I, Barge RM, Willemze R, Falkenburg JH. Hoogendoorn M, et al. Among authors: barge rm. Clin Cancer Res. 2005 Jul 15;11(14):5310-8. doi: 10.1158/1078-0432.CCR-04-2425. Clin Cancer Res. 2005. PMID: 16033850 Clinical Trial.

10

Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning.

Kalpoe JS, van der Heiden PL, Vaessen N, Claas EC, Barge RM, Kroes AC. Kalpoe JS, et al. Among authors: barge rm. Bone Marrow Transplant. 2007 Jul;40(2):137-43. doi: 10.1038/sj.bmt.1705701. Epub 2007 May 28. Bone Marrow Transplant. 2007. PMID: 17530007

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61 results

Search Page

Filters